Abstract
No public abstract is available from the verified source records.
Pousali Mitra, Akash Panja, Rashmi Pirthwar, Bat Chen R. Lubin, Dror Tobi, Gary Gellerman
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The global burden of lung Cancer: current status and future trends
10.1038/s41571-023-00798-3 · 2023
Lung Cancer
10.1016/s0140-6736(21)00312-3 · 2021
A review on non-small cell lung Cancer
10.1016/j.vacun.2023.12.003 · 2024
Acute and late toxicities of concurrent chemoradiotherapy for locally-advanced non-small cell lung cancer
10.3390/cancers9090120 · 2017
Radiation therapy-associated toxicity: Etiology, management, and prevention
2021
New light on chemotherapy toxicity and its prevention
10.1038/s44276-024-00064-8 · 2024
The incidence and severity of patient-reported side effects of chemotherapy in routine clinical care: a prospective observational study
2023
Epidermal growth factor receptor mutations in lung Cancer
10.1038/nrc2088 · 2007
Synthesis and anticancer properties of novel Dolastatin 10 Analogs featuring five-membered heterocyclic rings with a linkable group at the C-terminus
10.1016/j.bmc.2024.117794 · 2024
The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
datacite
Confidence 0%
10.2147/cmar.s186042 · 2019
Portrazza (Necitumumab), an IgG1 monoclonal antibody, FDA approved for advanced squamous non–small-cell lung cancer
2016
10.2147/ott.s114039
10.2147/ott.s114039
Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance
10.1158/1535-7163.mct-17-0575 · 2018
Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
10.1016/j.apsb.2022.07.020 · 2023
Peptide-drug conjugates as next-generation therapeutics: exploring the potential and clinical progress
10.3390/bioengineering12050481 · 2025
Recent innovations in peptide based targeted drug delivery to cancer cells
10.3390/biomedicines4020011 · 2016
Antibody–drug conjugates (ADCs): a review of structural design, technological evolution, and future perspectives
10.3390/molecules31071180 · 2026
Peptide-drug conjugates: a new hope for cancer
10.1002/psc.70040 · 2025
Peptide-drug conjugates: a new paradigm for targeted Cancer therapy
10.1016/j.ejmech.2023.116119 · 2024
Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer
10.1056/nejmoa2107322 · 2021
177Lu-DOTATATE for the treatment of Gastroenteropancreatic neuroendocrine Tumors
10.1080/17474124.2019.1685381 · 2019
Phage display
10.1021/cr960065d · 1997
Novel cyclic peptides for targeting EGFR and EGRvIII mutation for drug delivery
10.3390/pharmaceutics14071505 · 2022
10.1073/pnas.94.23.12297
10.1073/pnas.94.23.12297
Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid
10.1073/pnas.81.13.3998 · 1984
10.3390/ijms25031798
10.3390/ijms25031798
High throughput virtual screening (HTVS) of peptide library: technological advancement in ligand discovery
10.1016/j.ejmech.2022.114766 · 2022
Advances in computer-aided drug design: from molecular docking to artificial intelligence-driven therapeutic discovery
10.1016/j.aspetd.2026.100024 · 2026
An in silico approach to design peptide mimetics based on docking and molecular dynamics simulation of EGFR–Matuzumab complex
10.1007/s13738-016-0898-7 · 2016
A rational approach for creating peptides mimicking antibody binding
10.1038/s41598-018-37201-6 · 2019
EGFR-targeted and MMP-activated membranolytic peptides kill Cancer cells specifically in vitro and reduce tumor growth in vivo
10.1021/acs.molpharmaceut.5c01774 · 2026
EGFR-binding peptides: from computational design towards tumor-targeting of adeno-associated virus capsids
10.3390/ijms21249535 · 2020
The afatinib resistance of in vivo generated H1975 lung Cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival Signaling
10.18632/oncotarget.7746 · 2016
EGFR in cancer: signaling mechanisms, drugs, and acquired resistance
10.3390/cancers13112748 · 2021
Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: current developments in medicinal chemistry
10.1002/med.21488 · 2018
Targeting EGFR T790M mutation in NSCLC: from biology to evaluation and treatment
10.1016/j.phrs.2017.01.003 · 2017
Peptide–drug conjugates bearing an antimitotic Ahx-DA1 payload achieve potent antitumor activity in Her2-amplified and EGFR-positive KRAS-mutant cancers in vivo
10.1016/j.bmc.2026.118674 · 2026
Unresolved referenced work
Kept as external metadata until matched
Applying unbiased, functional criteria allows selection of novel cyclic peptides for effective targeted drug delivery to malignant prostate cancer cells
10.3390/pharmaceutics17070866 · 2025
Cell-penetrating peptides selectively cross the blood-brain barrier in vivo
10.1371/journal.pone.0139652 · 2015
The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling
10.1002/prot.23106 · doi-reference
Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring
10.1021/jm060522a · doi-reference
Nosé–Hoover chains: the canonical ensemble via continuous dynamics
10.1063/1.463940 · doi-reference
OPLS4: improving force field accuracy on challenging regimes of chemical space
10.1021/acs.jctc.1c00302 · doi-reference
10.33140/oajast.04.02.06
10.33140/oajast.04.02.06 · doi-reference
Mechanisms of cutaneous toxicities to EGFR inhibitors
10.1038/nrc1970 · doi-reference
10.1016/j.jconrel.2026.114993
10.1016/j.jconrel.2026.114993 · doi-reference
Novel cyclic peptide–drug conjugate P6-SN38 toward targeted treatment of EGFR overexpressed non-small cell lung cancer
10.3390/pharmaceutics16121613 · doi-reference
EGFR-mediated expression of Aquaporin-3 is involved in human skin fibroblast migration
10.1042/bj20060816 · doi-reference
A fluorogenic probe for predicting treatment response in non-small cell lung Cancer with EGFR-activating mutations
10.1038/s41467-022-34627-5 · doi-reference
HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib
10.3892/ol.2016.5373 · doi-reference
Site-specific stabilization of Minigastrin Analogs against enzymatic degradation for enhanced Cholecystokinin-2 receptor targeting
10.7150/thno.24378 · doi-reference